louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05988671: Intraperitoneal Dexamethasone, Dexmedetomidine, and Dexamethasone-Dexmedetomidine Combination on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy
Official title: Comparison of Intraperitoneal Dexamethasone, Dexmedetomidine, and Dexamethasone-Dexmedetomidine Combination on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Laparoscopic Cholecystectomy
Postoperative Nausea and Vomiting
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
Collaborators: name: Benha University
First posted: 2023-08-14
Enrollment: 120
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Nausea and vomiting are some of the most common complaints of patients after any anesthesia, which is often associated with postop-erative pain. The double-blind clinical trial study aimed to compare the prophylactic effect of dexamethasone and dexmedetomidine and their combination in reducing postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.


Eligibility criteria: Inclusion Criteria:

* Patients aged from 20 - 50 years
* ASA I OR II
* undergo laparoscopic cholecystectomy

Exclusion Criteria:

* Patients with history of psychotic illnesses,
* Parkinson's disease
* motion disorder
* Smoker
* or history of chemotherapy

Primary outcomes:
measure: The number of patients suffered from postoperative nausea and vomiting will be recorded in each group.
timeFrame: 24 hours postoperative
Secondary outcomes:
measure: antiemetic consumption
timeFrame: 24 hours postoperatively
Other outcomes:
Locations:
city: Banhā
country: Egypt
facility: Haney Baumey
city: Tanta
country: Egypt
facility: Neveen Kohaf
Study officials:
References:
Clinical trial NCT06884371: Lumbar Paraspinal Muscle Fatty Infilteration
Official title: Is a Complete Fatty Infilteration of Lumbar Paraspinal Muscles an Indicator to a Serious Pathology: A Case Report
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Muscle Weakness
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-03-19
Enrollment: 1
Sex: MALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A 22-year-old man who used to work eight hours a day sitting for a long time in an office

Brief summary: Introducing a unique clinical case of limb-girdle muscular dystrophy associated with LBP that was initially misdiagnosed as non-specific LBP

Detailed description: This case report describes the history, examination findings, and clinical reasoning used for a patient suffering from LBP as a chief complaint. A new sign appeared in MRI, which prompted the author to change the diagnosis process from lower back pain to a mysterious neurological disease, The MRI revealed widespread fat deposit in the lumbar paraspinal muscles. This MRI sign prompted the authors to do more lab investigation, showing a notably elevated level of creatinine phosphokinase (906 u/L). Further clinical examination revealed proximal muscle weakness, winging of scapula and Bilateral LMN facial palsy. Therefore, the patient was ultimately directed to a neurologist who confirmed the diagnosis of limb-girdle muscular dystrophy

Eligibility criteria: Inclusion Criteria:

* experiencing lower back stiffness and a dull back pain

Exclusion Criteria:

* diabetes, heart disease, or muscle disease. any history of previous falls, accidents, surgeries, hospitalizations, and he denied any significant past illnesses, or allergies.

Primary outcomes:
measure: An MRI of the lumbar spine
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Faculty of Physical Therapy
Study officials:
References:
Clinical trial NCT06875271: Inclinometer Reliability in Seated Shoulder Position Sense Assessment
Official title: Inclinometer Assessment of Seated Shoulder Position Sense: Intra- and Inter-Rater Reliability and Validity
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Position Sense
Lead sponsor: Fatih Sultan Mehmet Training and Research Hospital
Sponsor class: OTHER
First posted: 2025-03-13
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy participants aged 18-60 with no current or past shoulder injury, trauma, or pain.

Brief summary: Inclinometer Assessment of Seated Shoulder Position Sense: Intra- and Inter-Rater Reliability and Validity


Eligibility criteria: Inclusion Criteria:

* Healthy participants aged 18-60 with no current or past shoulder injury, trauma, or pain.

Exclusion Criteria:

* Pain in the upper extremity or neck
* Limited range of motion in the upper extremity joints
* Any history of upper extremity, cervical, or cranial injury
* Regular involvement in a sport or occupation that requires frequent overhead shoulder movements
* Performing strenuous exercise within 24 hours prior to the assessment
* Consumption of alcohol and/or illicit substances within 24 hours prior to the assessment

Primary outcomes:
measure: Position Sense
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Liv hospital Vadistanbul
Study officials:
affiliation: Liv hospital vadistanbul
name: pmr specialist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03451071: Postpartum HPV Vaccination
Official title: Postpartum HPV Vaccination: Acceptability, Uptake and Immunogenicity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: HPV-Related Malignancy
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2018-03-01
Enrollment: 195
Sex: FEMALE
Minimum age (years): 16
Maximum age (years): 26
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Human papillomavirus (HPV)-related cancers are on the rise in the United States. Furthermore, greater than 90% of cervical cancer cases are attributable to HPV, and cervical cancer disproportionately affects women of color in both incidence and mortality. Due to low HPV vaccine uptake in the US, innovative approaches to vaccinating vulnerable populations are necessary in order to maximize the cancer prevention potential of this vaccine. The puerperium is a time period when women are engaged in the healthcare system and have almost universal access to affordable health care. Two prior studies have shown that postpartum HPV vaccination is acceptable to patients, and high rates of vaccination were achieved in these primarily Hispanic populations. However, data show that the immune response in young women is less robust than in adolescents, and no studies have examined immunogenicity in postpartum women specifically. We propose an HPV vaccination pilot study in women who receive postpartum care at University of Alabama at Birmingham (UAB) hospital. We will examine the acceptability, uptake and immunogenicity of the vaccine in the postpartum setting.


Eligibility criteria: Inclusion Criteria:

* postpartum day 0-4 after vaginal or Cesarean delivery at UAB hospital

Exclusion criteria

* Fetal demise or miscarriage, autoimmune disorder, HIV, Hepatitis B/C, chronic steroid use, preeclampsia, non-English speaking

Primary outcomes:
measure: Patient Indication of Willingness to Accept the Vaccine Based on Survey
timeFrame: 1 day (at the time of initial recruitment /survey)
Secondary outcomes:
measure: Uptake of the Vaccine Doses
timeFrame: at baseline
measure: Uptake of the Vaccine Doses
timeFrame: at 3 months
measure: Uptake of the Vaccine Doses
timeFrame: at 6 months
measure: Serum Titers of Vaccine-specific HPV Types
timeFrame: baseline and 7 months
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
References:
Clinical trial NCT00856271: Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
Official title: A Randomized, Double-blind, Double-dummy, Multi-center Study to Investigate the Safety and Efficacy of Olmesartan Medoxomil Compared With Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Essential Hypertension
Lead sponsor: Daiichi Sankyo
Sponsor class: INDUSTRY
Collaborators: name: Shanghai Sankyo Pharmaceuticals Co., Ltd.
First posted: 2009-03-05
Enrollment: 287
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.


Eligibility criteria: Inclusion Criteria:

* mild to moderated essential hypertension (mean seated diastolic blood pressure ≥ 95 mmHg and \<110 mmHg, mean seated systolic blood pressure \< 180 mmHg)
* able to give written informed consent

Exclusion Criteria:

* known or suspected secondary hypertension
* history of chronic hepatic diseases
* obstructive hypertrophic cardiomyopathy/clinically significant valvular heart disease
* cardiac arrhythmia
* unstable angina pectoris
* congestive heart insufficiency (New York Heart Association classification III-IV)
* bilateral renal artery stenosis
* isolated renal artery stenosis
* post renal transplantation
* history of acute myocardial infarction/percutaneous transluminal coronary angioplasty or heart surgery within three months before enrollment
* retina bleeding/effusion
* insulin dependent diabetes mellitus
* uncontrolled non-insulin dependent diabetes mellitus

Primary outcomes:
measure: Change of trough seated diastolic blood pressure from baseline to 8 weeks
timeFrame: Baseline to 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
city: Chongqing
country: China
city: Guang Zhou
country: China
city: Nanjing
country: China
city: Shanghai
country: China
Study officials:
affiliation: Sankyo Shanghai Pharmaceuticals
name: Vice President
role: STUDY_DIRECTOR
References:
Clinical trial NCT03049371: Exploration of the Neo-Vagina Study
Official title: Thai Red Cross AIDS Research Center
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Transgender Women
Lead sponsor: Thai Red Cross AIDS Research Centre
Sponsor class: OTHER
Collaborators: name: amfAR, The Foundation for AIDS Research
First posted: 2017-02-10
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The current study will explore behavioral, surgical and biological neovaginal and rectal HIV transmission risks and feasibility of collection of blood and ano-genital samples (rectal, genital and neo-vaginal, including urine) for microbiological, immunological and cytological characterization in the context of antiretroviral chemoprophylaxis for the prevention of HIV infection in TGW. This includes the feasibility of home self-collection of ano-genital samples prior to habitual cleansing of the anatomical collection site.

Detailed description: A computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant. The questionnaire can be completed online from any location or at the study clinic and will take about 15-20 minutes.

Eligibility criteria: Inclusion Criteria:

Participants will be recruited through existing social networks among TGW and from the Thai Red Cross Anonymous and Tangerine Clinics providing HIV testing, care and treatment services. TGW attending clinic services will be offered enrollment in the study. Particular attention will be paid to offering enrollment to those attending HIV treatment and care services. The current study offers medical evaluation and a range of laboratory testing specific to the health of TGW, which may be of interest and beneficial to them. At the same time, the study may benefit from their participation.

Exclusion Criteria:

not TGW

Primary outcomes:
measure: important information regarding the willingness and obstacles for TGW to come forward for neo-vaginal and rectal HIV and STI evaluation, a computer-administered questionnaire.
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Pathum Wan
country: Thailand
facility: The Thai Red Cross AIDS Research Centre
state: Bangkok
Study officials:
affiliation: The Thai Red Cross AIDS Research Centre
name: Frits van Griensven, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04470271: Re-linkage to Care of Patients With Hepatitis C
Official title: Effectiveness of Implementing a Strategy to Re-linkage to Care of Patients With Hepatitis C Who Were Lost to Follow-up
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Viral Hepatitis C
Keywords: viral infection
outcome
antiviral therapy
Lead sponsor: Austral University, Argentina
Sponsor class: OTHER
First posted: 2020-07-14
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with history of chronic HCV infection who were lost of follow up.

Brief summary: The purpose of this study is to identify patients with chronic hepatitis C virus (HCV) who were lost of follow up and relinkage them to hepatitis C care

Detailed description: The investigators will review electronic medical charts to identify patients with HCV diagnosis. Next, investigators will evaluate if these patients are routinely followed by liver specialists at the Institution. Those patients who were lost of follow up will be reached to evaluate their disease and eventually offer them to restart HCV care.

Eligibility criteria: Inclusion Criteria:

* Patients older than 18 years
* Patients clinically evaluated at least once in the participating medical center
* chronic HCV infection

Exclusion Criteria:

* There are no exclusion criteria

Primary outcomes:
measure: Number of participants who were lost of follow up
timeFrame: through study completion, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Pilar
country: Argentina
facility: Universidad Austral
state: Buenos Aires
Study officials:
affiliation: Austral University, Argentina
name: Marcelo O Silva, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01338571: Horton & Maizy Pilot Study for Resistant to Starch
Official title: The Effect of Resistant Starch on the Stool Microflora of Children: A Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: pH
Weight Gain
Keywords: stool fatty acid
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
First posted: 2011-04-19
Enrollment: 4
Sex: ALL
Minimum age (years): 5
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children between ages 5 and 15

Brief summary: This is a pilot study and will be used to power an NIH grant application on the effect of resistant starch on weight gain in children.

Detailed description: Stool fatty acids and stool pH from the baseline and week 4 stool samples will be compared by paired-t test. The stool microflora changes will be reported using descriptive statistics for the percent changes in the different bacterial phyla.

Eligibility criteria: Inclusion Criteria:

* Healthy male or female between the ages of 5 and 15 years

Exclusion Criteria:

* Gastrointestinal disease
* Medication such as antibiotics that have the potential for altering the gut bacterial flora.
* Allergic to milk or corn products.

Primary outcomes:
measure: Effect of resistant starch on weight gain in children
timeFrame: Four weeks
Secondary outcomes:
measure: Effect of resistant starch on weight gain in children
timeFrame: Four weeks
Other outcomes:
Locations:
city: Baton Rouge
country: United States
facility: Pennington Biomedical Research Center
state: Louisiana
Study officials:
References:
Clinical trial NCT06105671: U-LABA/ICS Effects on Exercise Performance, Formoterol
Official title: Physiological Responses to U-LABA/ICS With Emphasis on Exercise Performance in Well-Trained Individuals, Formoterol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise Performance
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2023-10-30
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the project is to investigate exercise performance in well-trained individuals in a crossover design following varying degrees of bronchodilation/constriction intervention using current standard procedures.


Eligibility criteria: Inclusion Criteria:

* Age 18-45
* Physically active \>5 hours a week
* Maximum oxygen uptake classified as high or very high

Exclusion Criteria:

* Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
* ECG abnormality
* FEV1/FVC ratio \< 0,7 determined with spirometry
* Chronic illness determined to be a potential risk for participant during the study
* In chronic treatments with medication that may interfere with study results
* Pregnancy
* Smoker
* Blood donation during the past 3 months

Primary outcomes:
measure: Power output during time trial
timeFrame: Through study completion, an average on 4 weeks
Secondary outcomes:
measure: Power output during sprint testing
timeFrame: Through study completion, an average on 4 weeks
Other outcomes:
measure: Quadriceps strength
timeFrame: Through study completion, an average on 4 weeks
measure: Forced Expiratory Volume in 1 second (FEV1)
timeFrame: Through study completion, an average on 4 weeks
measure: Respiratory muscle function
timeFrame: Through study completion, an average on 4 weeks
Locations:
city: Copenhagen
country: Denmark
facility: August Krogh Building
Study officials:
affiliation: University of Copenhagen
name: Morten Hostrup, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01992471: Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing
Official title: Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: BRCA1 testing
BRCA2 testing
13-215
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2013-11-25
Enrollment: 197
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will also be eligible if they are referred to the MSKCC Clinical Genetics Service from outside providers after receiving negative full sequence BRCA1/2 results from those outside providers.

Brief summary: The purpose of this study is to find out what kinds of information people would like to receive from a new kind of genetic testing, and how they respond to this new kind of testing.


Eligibility criteria: Inclusion Criteria:

* Male or Female age 18 or older
* Personal history of breast cancer AND one of the following:
* Invasive breast cancer or DCIS diagnosed at or before age 45 Invasive breast cancer diagnosed at/before age 50 with one or more of the following:
* Limited family history (Fewer than 2 first- or second-degree female relatives in the same lineage that lived to age 45. The "limited family history" can occur on either the maternal or paternal side of the family.)
* 1 or more first-/second-degree relatives with invasive BC at/before 50
* 1 or more first-/second-degree relatives with invasive epithelial ovarian cancer (any age)
* 1 or more first- or second-degree relatives with male breast cancer
* 2 or more first- or second-degree relatives with pancreas cancer
* Invasive breast cancer diagnosed at or before age 60 with at least 2 first or second-degree relatives affected with any combination of invasive breast cancer before age 50, invasive epithelial ovarian cancer at any age, male breast cancer, or pancreas cancer.
* Full sequence BRCA1 and BRCA2 testing completed with no deleterious mutation identified.

Exclusion Criteria:

* Unable to provide informed consent for testing
* Unable to complete English language questionnaire

Primary outcomes:
measure: women's preferences with respect to the type of information they would like to receive from multiplex testing
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Mark Robson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01361971: Hyperbaric Oxygen Treatment Ameliorates Insulin Resistance
Official title: Hyperbaric Oxygen Treatment Ameliorates Insulin Resistance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Type 2 Diabetes
Keywords: Insulin resistance
Inflammation
Hypoxia
Lead sponsor: University of Adelaide
Sponsor class: OTHER
First posted: 2011-05-27
Enrollment: 20
Sex: MALE
Minimum age (years): 45
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Obesity is an epidemic in Western society and is the biggest risk factor for insulin resistance and type 2 diabetes. The investigators have preliminary evidence showing that hyperbaric oxygen therapy rapidly increases insulin sensitivity in humans. This requires confirmation in a larger population, and with this study the investigators will also test for mechanisms how this occurs. The investigators suspect that modulation of hypoxia and stress response proteins following changes in tissue oxygenation may contribute to these improvements. This study has the potential to yield new and important insights into the insulin resistance in obesity.


Eligibility criteria: Inclusion Criteria:

* Obese men with and without type 2 diabetes aged 45-70
* Lean men without type 2 diabetes aged 45-70

Exclusion Criteria:

* smokers
* claustrophobic
* sleep apnoea
* blood donor
* exercise more than 2 times per week
* under certain medications eg: bleomycin,corticosteroid

Primary outcomes:
measure: Insulin sensitivity
timeFrame: 1 year
Secondary outcomes:
measure: Hypoxia and inflammatory markers
timeFrame: 1 year
Other outcomes:
Locations:
city: Adelaide
country: Australia
facility: University of Adelaide
state: South Australia
Study officials:
affiliation: University of Adelaide
name: Leonie K Heilbronn, Phd
role: PRINCIPAL_INVESTIGATOR
References: